00314 思派健康
SIPAI HEALTH
SIPAI HEALTH
| Listing Date | 2022/12/23 |
| Listing Price | 18.600 |
Subscription Result
- Subscription Rate8.27x
- Guarantee One Lot Size15 lot
- One Lot Success Rate15%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Sipai Health Technology Co. engages three business lines, Specialty Pharmacy Business, Physician Research Assistance and Health Insurance Services, which are highly synergistic.
--
1.Its Specialty Pharmacy Business line consists of specialty pharmacy and value-add professional pharmacist service, focusing on specialty medicines for the treatment of oncology and other critical diseases. As of June 30, 2022, it operated 103 specialty pharmacies across all provincial administrative regions in mainland China. The Group is the largest privately owned specialty pharmacy in China, as measured by specialty medicine revenue in 2021.
2.In Physician Research Assistance business line, it engages in SMO business to support pharmaceutical companies in their drug R&D process from phase I to phase IV clinical trials. As of June 30, 2022, it had completed 99 SMO projects, and 936 SMO projects were ongoing. It had cumulatively served 289 clients across trial sites in 87 cities. It rank fourth in the general SMO market and first in oncology SMO market in China, as measured in revenue in 2021.
3.Health Insurance Services: As of June 30, 2022, its health service provider network connected over 1,200 Class III Grade A hospitals, 55,000 doctors, and 500 physical examination institutions in over 150 major cities across China. It served approximately 23.9 million individual members and 876 enterprise clients.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 9.92M shares |
| No. of International Offer Shares | 8.93M shares |
| No. of HK Offer Shares | 0.99M shares |
| Offer Price | $18.60 |
| Stock Code | 314 |
| Sponsor(s) | Morgan Stanley Asia Limited, Haitong International Capital Limited |
| Underwriter(s) | Morgan Stanley Asia Limited, Haitong International Securities Company Limited, Futu Securities International (Hong Kong) Limited, Maxa Capital Limited, I Win Securities Limited |
TIME TABLE
| Application Period | Dec 12 (Mon) - noon, Dec 15 (Thu) |
| Price Determination Date | Dec 15 (Thu) |
| Result Announcement Date | On or before Dec 22 (Thu) |
| Result Announcement Date | On or before Dec 22 (Thu) |
| Dealings in Shares commence on | Dec 23, 2022. (Fri) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $18.60 |
| Capitalization | 14.19B |
| NAV / share ($) | $2.70 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 18.60, the net proceeds raised would be HKD 120.40M, of which |
| 35% : Further expansion of Specialty Pharmacy Business |
| 28% : Further expansion of our Physician Research Assistance business |
| 24% : Further expansion of Health Insurance Services business |
| 13% : Used for technology research and development as well as technology infrastructure enhancement |
IPO NEWS
| 23/12/2022 16:08 |
| {New Stock}SIPAI HEALTH(00314) ends up 34.41% at HK$25 |
| 23/12/2022 09:20 |
| {New Stock}SIPAI HEALTH(00314) opens up 27.42% at HK$23.7 |
| 22/12/2022 16:20 |
| {New Stock}SIPAI HEALTH up 11.83% at HK$20.8 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).